Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes

References

• American Diabetes AssociationStandards of medical care in diabetesDiabetes Care201841Suppl 1S1S15929222369
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and ResearchGuidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdfAccessed August 10, 2018
   Google Scholar
• FoxCSPencinaMJWilsonPWPaynterNPVasanRSD’AgostinoRBLifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart studyDiabetes Care20083181582158418458146
   PubMed Web of Science ®Google Scholar
• RydénLGrantPJAnkerSDESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEur Heart J2013343035308723996285
   PubMed Web of Science ®Google Scholar
• UlusoySAssessment of cardiovascular risk in hypertensive patients: a comparison of commonly used risk scoring programsKidney Int Suppl201334340342
   Web of Science ®Google Scholar
• HanYChoYEAyonRSGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary arteryAm J Physiol Lung Cell Mol Physiol20153099L1027L103626361875
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
   PubMed Web of Science ®Google Scholar
• KalraSSodium Glucose Co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacologyDiabetes Ther20145235536625424969
   PubMed Web of Science ®Google Scholar
• PoulsenSBFentonRARiegTSodium-glucose cotransportCurr Opin Nephrol Hypertens201524546346926125647
   PubMed Web of Science ®Google Scholar
• PolidoriDShaSMudaliarSCanagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDiabetes Care20133682154216123412078
   PubMed Web of Science ®Google Scholar
• DevineniDPolidoriDClinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitorClin Pharmacokinet201554101027104126041408
   PubMed Web of Science ®Google Scholar
• SteinPBergJKMorrowLCanagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trialMetabolism201463101296130325110280
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality Total expenditures in millions by prescribed drug, United States19962015Medical Expenditure Panel SurveyAgency for Healthcare Research and Quality2018 Available from: https://meps.ahrq.gov/mepstrends/hc_pmed/GeneratedinteractivelyAccessed November 8, 2018
   Google Scholar
• NealBPerkovicVMahaffeyKWCanagliflozin and cardiovascular and renal events in type 2 diabetesN Engl J Med Overseas Ed20173777644657
   PubMed Web of Science ®Google Scholar
• KosiborodMCavenderMAFuAZLower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)Circulation2017136324925928522450
   PubMed Web of Science ®Google Scholar
• PatornoEGoldfineABSchneeweissSCardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort studyBMJ2018360k11929437648
   PubMed Web of Science ®Google Scholar
• TownsendRRMachinIRenJReductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertensionJ Clin Hypertens20161814352
   PubMed Web of Science ®Google Scholar
• YaleJFBakrisGCariouBEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes Obes Metab201315546347323464594
   PubMed Web of Science ®Google Scholar
• WeirMRJanuszewiczAGilbertREEffect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitusJ Clin Hypertens20141612875882
   PubMed Web of Science ®Google Scholar
• WildingJPCharpentierGHollanderPEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialInt J Clin Pract201367121267128224118688
   PubMed Web of Science ®Google Scholar
• Lavalle-GonzálezFJJanuszewiczADavidsonJEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia201356122582259224026211
   PubMed Web of Science ®Google Scholar
• SchernthanerGGrossJLRosenstockJCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialDiabetes Care20133692508251523564919
   PubMed Web of Science ®Google Scholar
• ForstTGuthrieRGoldenbergREfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazoneDiabetes Obes Metab201416546747724528605
   PubMed Web of Science ®Google Scholar
• RosenstockJAggarwalNPolidoriDDose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetesDiabetes Care20123561232123822492586
   PubMed Web of Science ®Google Scholar
• NeuenBLOhkumaTNealBCardiovascular and renal outcomes with canagliflozin according to baseline kidney functionCirculation2018138151537155029941478
   PubMed Web of Science ®Google Scholar
• SanoMTakeiMShiraishiYSuzukiYIncreased hematocrit during sodium-glucose Cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneysJ Clin Med Res201681284484727829948
   PubMedGoogle Scholar
• Invokana^® (canagliflozin tablet, film coated) [package insert]Titusville, NJJanssen Pharmaceuticals, Inc.2018
   Google Scholar
• JardineMJMahaffeyKWNealBThe canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristicsAm J Nephrol201746646247229253846
   PubMed Web of Science ®Google Scholar
• MahaffeyKNealBPerkovicVCanagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)Circulation20181374324334
   Web of Science ®Google Scholar
• CherneyDZPerkinsBASoleymanlouNThe effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitusCardiovasc Diabetol20141312824475922
   PubMed Web of Science ®Google Scholar
• ChiltonRTikkanenICannonCPEffects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes Obes Metab201517121180119326343814
   PubMed Web of Science ®Google Scholar
• TownsendRDharmalingamMGenoveseSImprovements in Blood Pressure (BP) and Markers of Arterial Stiffness with Cana-gliflozin (CANA) in the CANagliflozin CardioVascular Assessment Study (CANVAS) ProgramDiabetes201867Supplement 11210-P
   Google Scholar
• PfeiferMTownsendRRDaviesMJVijapurkarURenJEffects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisCardiovasc Diabetol20171612928241822
   PubMed Web of Science ®Google Scholar
• RamirezAJSanchezMJSanchezRADiabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindoprilJ Hypertens Epub2018814
   Web of Science ®Google Scholar
• VermaSGargAYanATEffect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial?Diabetes Care20163912e212e21327679584
   PubMed Web of Science ®Google Scholar
• HabibiJAroorARSowersJRSodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetesCardiovasc Diabetol2017161928086951
   PubMedGoogle Scholar
• MatsutaniDSakamotoMKayamaYTakedaNHoriuchiRUtsunomiyaKEffect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetesCardiovasc Diabetol20181717329788955
   PubMedGoogle Scholar
• JanuzziJLButlerJJarolimPEffects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetesJ Am Coll Cardiol201770670471228619659
   PubMed Web of Science ®Google Scholar
• BakerWLSmythLRRicheDMBourretEMChamberlinKWWhiteWBEffects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysisJ Am Soc Hypertens20148426227524602971
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• AstraZenecaFarxiga achieved a positive result in the Phase III DECLARE-TIMI 58 trial, a large cardiovascular outcomes trial in 17,000 patients with type-2 diabetes [press release]AstraZeneca-Research-Based BioPharmaceutical Company2018 Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018.htmlAccessed October 20, 2018
   Google Scholar
• TanakaANodeKIncreased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?Cardiovasc Diabetol201716112929025400
   PubMedGoogle Scholar
• FadiniGPAvogaroASGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting SystemLancet Diabetes Endocrinol20175968068128733172
   PubMed Web of Science ®Google Scholar
• RinkelWDLuitenJvan DongenJIn-hospital costs of diabetic foot disease treated by a multidisciplinary foot teamDiabetes Res Clin Pract2017132687828802698
   PubMed Web of Science ®Google Scholar
• YuanZDefalcoFJRyanPBRisk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort studyDiabetes Obes Metab201820358258928898514
   PubMed Web of Science ®Google Scholar
• GingerichCPFDA Accepts Zynquista NDA for Type 1 DiabetesMD Magazine Available from: https://www.mdmag.com/medical-news/fda-accepts-zynquista-nda-for-type-1-diabetes. Published May 22, 2018Accessed October 20, 2018
   Google Scholar
• GargSKHenryRRBanksPEffects of sotagliflozin added to insulin in patients with type 1 diabetesN Engl J Med2017377242337234828899222
   PubMed Web of Science ®Google Scholar
• ChenJFanFWangJYThe efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisSci Rep2017714412828276512
   PubMedGoogle Scholar
• TanakaAInoueTKitakazeMRationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trialCardiovasc Diabetol2016155727044332
   PubMed Web of Science ®Google Scholar